Today's announcement is seen as irrelevant, with Nexavar several months ahead in the approval process. Nexavar has established itself as the best-in-class treatment given its superior safety profiling for multiple conditions.
Progen should now turn its attention to the next-generation compound, with the viability of PI-88 coming under the microscope. Expect this one to trade down to cash value in the near term.
nexavar to dominate in us and europe
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.005(1.12%) |
Mkt cap ! $72.46M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 44.0¢ | 44.0¢ | $10.48K | 23.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1124106 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 1389 | 1 |
View Market Depth
| Last trade - 10.10am 12/07/2024 (20 minute delay) ? |
| PGL (ASX) Chart |